🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 60% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Tablet(s) Serving Size
Other Combinations Product Type
60% Evidence Coverage

Supplement Facts — Evidence Check

Iron
90 mg
1 mg
✅ 2.5× RDA — within safe limits 📚 225 studies (Tier A: 10, B: 105)
RDA 0.4mg This product: 1mg UL 1.0mg
12 mcg
📊 5.0× RDA — above typical dose 📚 138 studies (Tier A: 1, B: 44)
RDA 0.0024mg This product: 0.012mg
Vitamin C
120 mg
📊 Market median: 4002.0mg (1 products) 📚 20 studies (Tier A: 0, B: 2)
This product: 50mg

Other Ingredients

Povidone Croscarmellose Sodium Acrylic Resin Color added Magnesium Stearate FD&C Yellow No. 5 Vitamin A Palmitate Magnesium Silicate FD&C Blue No. 1 Polyethylene Glycol Ethyl Vanillin

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (99% of products) Structure/Function (71% of products) Nutrient (61% of products) Approved Health (1% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Clinical Pharmacology: Oral iron is absorbed most efficiently when administered between meals.

Precautions: General: Take 2 hours after meals.

Dosage and Administration: One tablet daily or as directed by a physician. Do not chew tablet.

⚠️ Warnings & Precautions

Indications and Usage: Ferralet 90 is indicated for the treatment of all anemias that are responsive to oral iron therapy. These include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, post-surgical convalescence, and dietary needs.

Contraindications: Hypersensitivity to any of the ingredients. Hemolytic anemia, hemochromatosis, and hemosiderosis are contraindications to iron therapy. Warning: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient.

Warning: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of the reach of children. In case of accidental overdose, call a doctor or poison control center immediately.

Do not exceed recommended dose. Discontinue use if symptoms of intolerance appear. The type of anemia and underlying cause or causes should be determined before starting therapy with Ferralet 90 tablets. Ensure Hgb, Hct, and reticulocyte counts are determined before starting therapy and periodically thereafter during prolonged treatment. Periodically review therapy to determine if it needs to be continued without change or if a dose change is indicated.

This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Folic Acid: Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive. pernicious anemia should be excluded before using these products since folic acid may mask the symptoms of pernicious anemia.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Geriatric Use: Dosing for elderly patients should be administered with caution. Due to the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy, dosing should start at the lower end of the dosing range. Adverse Reactions: Adverse reactions with iron therapy may include GI irritation, constipation, diarrhea, nausea, vomiting, and dark stools. Adverse reactions with iron therapy are usually transient.

Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

Drug Interactions: Prescriber should be aware of a number or iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.

Overdosage: Symptoms: abdominal pain, metabolic acidosis, anuria, CNS damage, coma, convulsions, death, dehydration, diffuse vascular congestion, hepatic cirrhosis, hypotension, hypothermia, lethargy, nausea, vomiting, diarrhea, tarry stools, melena, hematemesis, tachycardia, hyperglycemia, drowsiness, pallor, cyanosis, lassitude, seizures, and shock.

To report a serious adverse event or obtain product information, call (800) 298-1087.

Rx Only

🧪 Formulation Notes

90 mg Dual-Iron Delivery

Iron is critical for normal hemoglobin synthesis to maintain oxygen transport for energy production and proper function of cells. Adequate amounts of iron are necessary for effective erythropoiesis. Iron also serves as a cofactor of several essential enzymes, including cytochromes, which are involved in electron transport. Folic acid is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis. Folic acid is the precursor of tetrahydrofolic acid, which is involved as a cofactor for transformylation reactions in the biosynthesis of purines and thymidylates of nucleic acids. Deficiency of folic acid may account for the defective deoxyribonucleic acid (DNA) synthesis that leads to megaloblast formation and megaloblastic macrocytic anemias. Vitamin B12 is essential to growth, cell reproduction, hematopoiesis, nucleic acid, and myelin synthesis. Deficiency may result in megaloblastic anemia or pernicious anemia.

Notice: Contact with moisture can discolor or erode the tablet. How Supplied: Ferralet 90 (NDC 0178-0089-90) is a green, modified rectangle shaped, film-coated tablet, debossed with "F6" on one side and blank on the other, and packaged in bottles of 90.

Additional Information

NDC 0178-0089-90 Rx Only

Storage: Store at 20 degrees C to 25 degrees C (68 degrees F to 77 degrees F), excursions permitted between 15 degrees C and 30 degrees C (between 59 degrees F and 86 degrees F). Brief exposure to temperatures up to 40 degrees C (104 degrees F) may be tolerated provided the mean kinetic temperature does not exceed 25 degrees C (77 degrees F); however, such exposure should be minimized.

Product Details

DSLD Entry Date 2020-11-21
Product Type Other Combinations
Form Tablet or Pill
DSLD ID 240128
Data Updated 2026-04-11

Research Evidence

566 Research Sources
56 Avg Quality Score
240 Meta Analysis
100 Clinical Trial
74 Systematic Review
71 Guideline
58 Rct
11 Cochrane Review
4 Regulatory Source
2 Other
2 Narrative Review
1 Observational
1 Openfda Safety
A Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency
Meta Analysis Nature medicine 2025
A Intermittent iron supplementation for reducing anaemia and its associated impairments in adolescent and adult menstruating women
Meta Analysis The Cochrane database of systematic reviews 2019
A Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors
Meta Analysis The Cochrane database of systematic reviews 2014
A Serum or plasma ferritin concentration as an index of iron deficiency and overload
Meta Analysis The Cochrane database of systematic reviews 2021
A Non-invasive diagnostic tests for Helicobacter pylori infection
Meta Analysis The Cochrane database of systematic reviews 2018
A Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
Meta Analysis The Cochrane database of systematic reviews 2022
A Wheat flour fortification with iron and other micronutrients for reducing anaemia and improving iron status in populations
Meta Analysis The Cochrane database of systematic reviews 2021
A Fortification of condiments and seasonings with iron for preventing anaemia and improving health
Meta Analysis The Cochrane database of systematic reviews 2023
A Screening and Supplementation for Iron Deficiency and Iron Deficiency Anemia During Pregnancy: US Preventive Services Task Force Recommendation Statement.
Guideline JAMA 2024
A Psychiatric and cognitive outcomes of iron supplementation in non-anemic children, adolescents, and menstruating adults: A meta-analysis and systematic review
Meta Analysis Neuroscience and biobehavioral reviews 2025
View all evidence for Iron →

Compare Similar Products

View all Iron products →